|
Sign In to gain access to subscriptions and/or personal tools.
|
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
Yagiz Uresin
Department of Pharmacology and Clinical Pharmacology, Istanbul Medical Faculty, Istanbul, Turkey, yagiz{at}istanbul.edu.tr
Addison A Taylor
Baylor College of Medicine, Houston, Texas, USA
Charles Kilo
Kilo Diabetes and Vascular Research Foundation-Washington University School of Medicine, St Louis, Missouri, USA
Diethelm Tschöpe
Ruhr-Universität Bochum, Bad Oeynhausen, Germany
Massimo Santonastaso
Unita Operativa di Medicina Generale, Ospedale Civile, Vittorio Veneto, Italy
Ghionul Ibram
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Hui Fang
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Andrew Satlin
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Objective. To assess the antihypertensive efficacy and safety of the combination of the direct renin inhibitor aliskiren and ramipril in patients with diabetes and hypertension.
Methods. In this double-blind, multicentre trial, 837 patients with diabetes mellitus and hypertension (mean sitting diastolic blood pressure [BP] > 95 and < 110 mmHg) were randomised to once-daily aliskiren (150 mg titrated to 300 mg after four weeks; n=282), ramipril (5 mg titrated to 10 mg; n=278) or the combination (n=277) for eight weeks. Efficacy variables were cuff mean sitting diastolic BP (msDBP) and mean sitting systolic BP (msSBP); 24-hour ambulatory BP, plasma renin activity (PRA) and plasma renin concentration (PRC) were also assessed.
Results. At week 8, aliskiren, ramipril and aliskiren/ramipril lowered msDBP (mean±SEM) by 11.3±0.5, 10.7±0.5 and 12.8±0.5 mmHg, and msSBP by 14.7±0.9, 12.0±0.9 and 16.6±0.9 mmHg, respectively. Aliskiren/ramipril provided superior msDBP reductions to ramipril (p=0.004) or aliskiren (p=0043) monotherapy; adding aliskiren to ramipril provided an additional mean BP reduction of 4.6/2.1 mmHg. Aliskiren monotherapy was non-inferior to ramipril for msDBP reduction (p=0.0002) and superior for msSBP reduction (p=0.021).All treatments significantly lowered mean 24-hour ambulatory BP. Aliskiren significantly reduced PRA from baseline as monotherapy (by 66%, p<0.0001) or in combination with ramipril (by 48%, p<0.0001), despite large increases in PRC in all treatment groups. Aliskiren was well tolerated as monotherapy or in combination with ramipril.
Conclusions. Combining aliskiren with ramipril provided a greater reduction in msDBP than either drug alone in patients with diabetes and hypertension.
Key Words: ambulatory blood pressure monitoring • diabetes mellitus • direct renin inhibitor • plasma renin activity
References
- Selby JV, Peng T., Karter AJ et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004;10:163-70.[Web of Science][Medline]
[Order article via Infotrieve]
- European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-71.[Abstract/Free Full Text]
- Messerli FH, Grossman E., Goldbourt U. Antihypertensive therapy in diabetic hypertensiv patients. Am J Hypertens 2001;14:12S-16S.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Giacchetti G., Sechi LA, Rilli S., Carey RM The reninangiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005;16:120-6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hanes DS, Nahar A., Weir MR The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Curr Hypertens Rep 2004;6:98-105.[Web of Science][Medline]
[Order article via Infotrieve]
- Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
- Ruggenenti P., Fassi A., Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.[Abstract/Free Full Text]
- Fisher ND, Hollenberg NK Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16:592-9.[Abstract/Free Full Text]
- Wolny A., Clozel JP, Rein J. et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-27.[Abstract/Free Full Text]
- Nussberger J., Wuerzner G., Jensen C., Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-E8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gradman AH, Schmieder RE, Lins RL, Nussberger J., Chiang Y., Bedigian MP Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-18.[Abstract/Free Full Text]
- Lees KR The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens 1992;10:(suppl)S3-S11.[CrossRef]
- de Leeuw PW, Lugtenburg PL, van Houten H., Looman JH, Birkenhager WH Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients. J Cardiovasc Pharmacol 1985; 7:1161-5.[Web of Science][Medline]
[Order article via Infotrieve]
- Weir MR, Bush C., Zhang J., Keefe DL, Satlin A. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur Heart J 2006;27(suppl):299(1796)[Abstract].
- Morikawa T., Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharm Stat 1995;5:297-306.[CrossRef][Medline]
[Order article via Infotrieve]
- Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet D 1998;351:1755-62. 18. Zhao C., Vaidyanathan S., Yeh C-M., Maboudian M., Dieterich H-A. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with diabetes. Clin Pharmacokinet 2006;45:1125-34.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Meisel S., Shamiss A., Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 1994;26:7-15.[Web of Science][Medline]
[Order article via Infotrieve]
- Neutel JM The importance of 24-h blood pressure control. Blood Press Monit 2001;6:9-16.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mitchell J., Oh B., Herron J., Chung J., Khan M., Satlin A. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006;8:P-209 [Abstract].[CrossRef]
- Vander AJ, Greelhoed GW Inhibition of renin secretion by Ang II. Proc Soc Exp Biol Med 1965;120:339-403.
- Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II- renin feedback interruption. J Am Soc Nephrol 2004;15:3126-33.[Abstract/Free Full Text]
- Matos JP, de Lourdes Rodrigues M., Ismerim VL, Boasquevisque EM, Genelhu V., Francischetti EA Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin Nephrol 2005;64:180-9.[Web of Science][Medline]
[Order article via Infotrieve]
- Karlberg BE Cough and inhibition of the renin-angiotensin system. J Hypertens 1993;11(suppl):S49-S52.[CrossRef]
- Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.[Abstract/Free Full Text]
- Lithell HO Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-09. 28. Jacobsen P., Andersen S., Rossing K., Jensen BR, Parving HH Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 8, No. 4,
190-200 (2007)
DOI: 10.3317/jraas.2007.028
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Andersen, M. H Weinberger, C. M Constance, M. A Ali, J. Jin, M. F Prescott, and D. L Keefe
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2009;
10(3):
157 - 167.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. S Sever, A. H Gradman, and M. Azizi
Managing cardiovascular and renal risk: the potential of direct renin inhibition
Journal of Renin-Angiotensin-Aldosterone System,
June 1, 2009;
10(2):
65 - 76.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. S. Nuzum and T. Merz
Macrovascular Complications of Diabetes Mellitus
Journal of Pharmacy Practice,
April 1, 2009;
22(2):
135 - 148.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Berl
Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system
Journal of Renin-Angiotensin-Aldosterone System,
March 1, 2009;
10(1):
1 - 8.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. E. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, B. Smith, N. Weissbach, M. Maboudian, J. Botha, and H. van Ingen
Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide
Circulation,
January 27, 2009;
119(3):
417 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dietz, R. Dechend, C.-M. Yu, M. Bheda, J. Ford, M. F. Prescott, and D. L. Keefe
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2008;
9(3):
163 - 175.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Ayalasomayajula, C.-M. Yeh, S. Vaidyanathan, B. Flannery, H. A. Dieterich, D. Howard, M. P. Bedigian, and W. P. Dole
Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects
J. Clin. Pharmacol.,
July 1, 2008;
48(7):
799 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, N. K. Hollenberg, and the AVOID Study Investigators
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
N. Engl. J. Med.,
June 5, 2008;
358(23):
2433 - 2446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Ingelfinger
Aliskiren and Dual Therapy in Type 2 Diabetes Mellitus
N. Engl. J. Med.,
June 5, 2008;
358(23):
2503 - 2505.
[Full Text]
[PDF]
|
|
|
|
|
